NPI: 1215359922 · WILSON, NC 27893 · General Acute Care Hospital · NPI assigned 01/15/2014
Authorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
| Authorized Official | LAWRENCE, CHARLOTTE (SECRETARY) |
| NPI Enumeration Date | 01/15/2014 |
Other providers sharing the same authorized official: LAWRENCE, CHARLOTTE
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 49,945 | $1.42M |
| 2019 | 60,647 | $1.62M |
| 2020 | 42,527 | $788K |
| 2021 | 42,259 | $1.28M |
| 2022 | 36,434 | $1.84M |
| 2023 | 45,789 | $2.37M |
| 2024 | 36,587 | $2.16M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 33,965 | 31,308 | $3.53M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 17,597 | 16,184 | $2.87M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 17,606 | 16,324 | $1.09M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1,955 | 1,648 | $609K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3,747 | 3,361 | $501K |
| 41899 | Unlisted procedure, dentoalveolar structures | 245 | 158 | $348K |
| 80053 | Comprehensive metabolic panel | 27,361 | 24,336 | $253K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 5,310 | 2,868 | $213K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 34,362 | 30,419 | $209K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 11,538 | 10,024 | $193K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 4,664 | 4,326 | $188K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5,862 | 5,384 | $171K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 498 | 473 | $128K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 275 | 240 | $117K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3,898 | 3,325 | $82K |
| 80305 | 2,494 | 2,133 | $82K | |
| 71045 | Radiologic examination, chest; single view | 3,486 | 3,128 | $78K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 155 | 141 | $70K |
| 81001 | 21,830 | 19,788 | $70K | |
| 71046 | Radiologic examination, chest; 2 views | 2,449 | 2,260 | $67K |
| 70450 | Computed tomography, head or brain; without contrast material | 406 | 370 | $66K |
| 36415 | Collection of venous blood by venipuncture | 35,949 | 30,990 | $60K |
| J7030 | Infusion, normal saline solution , 1000 cc | 2,860 | 2,198 | $54K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1,799 | 1,476 | $45K |
| J7120 | Ringers lactate infusion, up to 1000 cc | 1,263 | 1,100 | $29K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2,387 | 2,299 | $28K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 885 | 270 | $28K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 43 | 38 | $24K |
| 84484 | 3,763 | 3,019 | $22K | |
| A9270 | Non-covered item or service | 34,895 | 19,638 | $22K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1,088 | 975 | $20K |
| 81025 | 2,733 | 2,481 | $19K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 54 | 54 | $18K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 977 | 878 | $15K |
| J3490 | Unclassified drugs | 5,119 | 2,538 | $14K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 663 | 620 | $9K |
| 85730 | 2,295 | 2,099 | $9K | |
| 83690 | 1,422 | 1,303 | $8K | |
| 59025 | Fetal non-stress test | 207 | 179 | $8K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 14 | 13 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1,416 | 1,322 | $6K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 215 | 183 | $6K |
| 80061 | Lipid panel | 494 | 430 | $6K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 371 | 355 | $6K |
| 85610 | 2,314 | 2,118 | $6K | |
| 82550 | 1,602 | 1,476 | $6K | |
| 83735 | 973 | 909 | $4K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 331 | 310 | $4K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 84 | 48 | $4K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 119 | 112 | $3K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 444 | 410 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | 344 | 295 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1,358 | 1,178 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 752 | 635 | $3K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 176 | 141 | $2K |
| 94726 | 31 | 27 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 318 | 295 | $2K |
| 87081 | 280 | 258 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 804 | 683 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 47 | 38 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 12 | 12 | $1K |
| J2704 | Injection, propofol, 10 mg | 199 | 166 | $1K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 155 | 126 | $1K |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | 716 | 440 | $1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 26 | 26 | $1K |
| 94729 | 46 | 41 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | 97 | 72 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 307 | 275 | $1K |
| 87807 | 95 | 91 | $1K | |
| 11045 | 18 | 13 | $998.75 | |
| 94060 | 43 | 38 | $985.03 | |
| 82553 | 121 | 116 | $714.74 | |
| 87088 | 126 | 113 | $710.49 | |
| 73130 | 15 | 13 | $700.31 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 179 | 165 | $510.62 |
| 82948 | 201 | 182 | $507.61 | |
| 73630 | 15 | 12 | $434.85 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 14 | 13 | $414.37 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 27 | 26 | $390.61 |
| 84439 | 65 | 45 | $389.89 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 152 | 147 | $370.30 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 96 | 48 | $330.64 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 29 | 12 | $297.54 |
| 87070 | 96 | 86 | $241.42 | |
| 83605 | 32 | 30 | $224.86 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 124 | 116 | $153.83 |
| 82565 | 39 | 38 | $146.01 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 29 | 28 | $142.60 |
| J7999 | Compounded drug, not otherwise classified | 78 | 77 | $135.94 |
| 87205 | 96 | 86 | $113.92 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 41 | 39 | $113.38 |
| 87186 | 16 | 14 | $96.55 | |
| J7050 | Infusion, normal saline solution, 250 cc | 28 | 25 | $86.50 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 50 | 36 | $85.60 |
| J3370 | Injection, vancomycin hcl, 500 mg | 52 | 52 | $71.47 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 57 | 56 | $70.14 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 52 | 52 | $62.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 13 | 12 | $25.07 |
| 84520 | 39 | 38 | $14.34 |